Foresight Global Investors’s Novo Nordisk NVO Stock Holding History

Foresight Global Investors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.8M	Sell	245,289 -110,285	-31%	-$4.74M	7.13%	7
2026 Q1	$13.1M	Buy	355,574 +25,323	+8%	+$1.2M	8.48%	4
2025 Q4	$16.8M	Buy	330,251 +164,957	+100%	+$8.44M	7.91%	5
2025 Q3	$9.17M	Sell	165,294 -76,872	-32%	-$4.5M	5.45%	10
2025 Q2	$16.7M	Buy	+242,166	New	+$16.5M	11.87%	4
2024 Q3	–	Sell	-101,702	Closed	-$14.5M	–	50
2024 Q2	$14.5M	Sell	101,702 -47,148	-32%	-$6.25M	6.98%	7
2024 Q1	$19.1M	Buy	+148,850	New	+$17.7M	9.41%	3

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Foresight Global Investors's NVO Position: Q2 2026 in Review

Foresight Global Investors reduced its Novo Nordisk (NVO) stake by 31% in Q2 2026, selling an estimated $4.74M and leaving 245,289 shares worth $11.8M. The position accounts for 7.13% of the portfolio, ranked #7.

Foresight Global Investors first reported a position in NVO in Q1 2024 and has held it in 7 quarters since. The position peaked at $19.1M in Q1 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Foresight Global Investors held 245,289 shares of Novo Nordisk worth $11.8M as of Q2 2026.
Foresight Global Investors sold 110,285 Novo Nordisk shares in Q2 2026, an estimated $4.74M.
Novo Nordisk made up 7.13% of Foresight Global Investors's portfolio in Q2 2026, its #7 holding.
Foresight Global Investors first reported a position in Novo Nordisk in Q1 2024 and has held it in 7 quarters since.
Foresight Global Investors's Novo Nordisk position peaked at $19.1M in Q1 2024.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Foresight Global Investors's 13F filing for Q2 2026, filed 11 Aug 2026.